Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2007
The primary objective of the study is to evaluate the safety and tolerability of 100, 200, and 300 mg/day doses of RWJ-445380 for up to 12 weeks in patients with active Rheumatoid Arthritis despite methotrexate therapy.
Epistemonikos ID: 7c246aaea3075b140d558d17f2be32bbb2441dda
First added on: Mar 23, 2022